Metabolic actions of estrogen receptor beta (ERβ) are mediated by a negative cross-talk with PPARγ

PLoS Genetics

Volumn 4, Issue 6, 2008, Pages

  Foryst Ludwig, Anna ^a   Clemenz, Markus ^a   Hohmann, Stephan ^a   Hartge, Martin ^a   Sprang, Christiane ^a   Frost, Nikolaj ^a   Krikov, Maxim ^a   Bhanot, Sanjay ^b   Barros, Rodrigo ^c   Morani, Andrea ^c   Gustafsson, Jan Åke ^c   Unger, Thomas ^a   Kintscher, Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ISIS PHARMACEUTICALS   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ESTROGEN RECEPTOR BETA; GLUCOSE; INSULIN; NUCLEAR RECEPTOR COACTIVATOR 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; STEROID RECEPTOR COACTIVATOR 1; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTISENSE OLIGONUCLEOTIDE; HISTONE ACETYLTRANSFERASE; TRANSCRIPTION FACTOR;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; IN VITRO STUDY; LIPID DIET; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; PROMOTER REGION; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WEIGHT GAIN; ADIPOCYTE; ANIMAL; CELL DIFFERENTIATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; GLUCOSE TOLERANCE TEST; HUMAN; METABOLIC DISORDER; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY;

MUS;

ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION; GLUCOSE; GLUCOSE TOLERANCE TEST; HISTONE ACETYLTRANSFERASES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METABOLIC DISEASES; MICE; MICE, KNOCKOUT; NUCLEAR RECEPTOR COACTIVATOR 2; OLIGONUCLEOTIDES, ANTISENSE; PPAR GAMMA; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 46249083607     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1000108     Document Type: Article

References (47)

1. Nilsson S, Gustafsson JA (2000) Estrogen receptor transcription and transactivation: Basic aspects of estrogen action. Breast Cancer Res 2: 360-366.
2. Smith CL, O'Malley BW (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25: 45-71.
3. Osborne CK, Schiff R (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23: 1616-1622.
4. McKenna NJ, O'Malley BW (2005) Teaching resources. An interactive course in nuclear receptor signaling: concepts and models. Sci STKE 2005: tr22.
5. Haslam DW, James WP (2005) Obesity. Lancet 366: 1197-1209.
6. Regitz-Zagrosek V (2006) Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 5: 425-438.
7. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO (2006) Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 95: 136-147.
8. Barros RP, Machado UF, Gustafsson JA (2006) Estrogen receptors: new players in diabetes mellitus. Trends Mol Med.
9. Carr MC (2003) The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88: 2404-2411.
10. Cooke PS, Heine PA, Taylor JA, Lubahn DB (2001) The role of estrogen and estrogen receptor-alpha in male adipose tissue. Mol Cell Endocrinol 178: 147-154.
11. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS (2000) Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci U S A 97: 12729-12734.
12. Naaz A, Zakroczymski M, Heine P, Taylor J, Saunders P, et al. (2002) Effect of ovariectomy on adipose tissue of mice in the absence of estrogen receptor alpha (ERalpha): a potential role for estrogen receptor beta (ERbeta). Horm Metab Res 34: 758-763.
13. Bryzgalova G, Gao H, Ahren B, Zierath JR, Galuska D, et al. (2006) Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver. Diabetologia 49: 588-597.
14. Ohlsson C, Hellberg N, Parini P, Vidal O, Bohlooly M, et al. (2000) Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. Biochem Biophys Res Commun 278: 640-645.
15. Semple RK, Chatterjee VK, O'Rahilly S (2006) PPAR gamma and human metabolic disease. J Clin Invest 116: 581-589.
16. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, et al. (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 91: 7355-7359.
17. Picard F, Auwerx J (2002) PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22: 167-197.
18. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351: 1106-1118.
19. Matsuzawa Y (2006) The metabolic syndrome and adipocytokines. FEBS Lett 580: 2917-2921.
20. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P (2006) Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 110: 267-278.
21. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26: 439-451.
22. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA (2005) Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev 19: 453-461.
23. Glass CK (2006) Going nuclear in metabolic and cardiovascular disease. J Clin Invest 116: 556-560.
24. Gronemeyer H, Gustafsson JA, Laudet V (2004) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3: 950-964.
25. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, et al. (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54: 3442-3452.
26. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79: 1147-1156.
27. Maxwell GM, Nobbs S, Bates DJ (1987) Diet-induced thermogenesis in cafeteria-fed rats: a myth? Am J Physiol 253: E264-270.
28. Frias JP, Yu JG, Kruszynska YT, Olefsky JM (2000) Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 23: 64-69.
29. Staels B, Fruchart JC (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54: 2460-2470.
30. Zhang YL, Hernandez-Ono A, Siri P, Weisberg S, Conlon D, et al. (2006) Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem 281: 37603-37615.
31. Lopez GN, Webb P, Shinsako JH, Baxter JD, Greene GL, et al. (1999) Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators. Mol Endocrinol 13: 897-909.
32. Keller H, Givel F, Perroud M, Wahli W (1995) Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol 9: 794-804.
33. Wang X, Kilgore MW (2002) Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells. Mol Cell Endocrinol 194: 123-133.
34. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8: 1224-1234.
35. Metzger D, Ali S, Bornert JM, Chambon P (1995) Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J Biol Chem 270: 9535-9542.
36. Tremblay A, Tremblay GB, Labrie F, Giguere V (1999) Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 3: 513-519.
37. Barros RP, Machado UF, Warner M, Gustafsson JA (2006) Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha. Proc Natl Acad Sci U S A 103: 1605-1608.
38. He W, Barak Y, Hevener A, Olson P, Liao D, et al. (2003) Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 100: 15712-15717. Epub 12003 Dec 15715.
39. Koutnikova H, Cock TA, Watanabe M, Houten SM, Champy MF, et al. (2003) Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc Natl Acad Sci U S A 100: 14457-14462. Epub 12003 Nov 14455.
40. Zhang J, Fu M, Cui T, Xiong C, Xu K, et al. (2004) Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci U S A 101: 10703-10708. Epub 12004 Jul 10712.
41. Sell H, Berger JP, Samson P, Castriota G, Lalonde J, et al. (2004) Peroxisome proliferator-activated receptor gamma agonism increases the capacity for sympathetically mediated thermogenesis in lean and ob/ob mice. Endocrinology 145: 3925-3934.
42. Picard F, Gehin M, Annicotte J, Rocchi S, Champy MF, et al. (2002) SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111: 931-941.
43. Follettie MT, Pinard M, Keith JC Jr, Wang L, Chelsky D, et al. (2006) Organ messenger ribonucleic acid and plasma proteome changes in the adjuvant-induced arthritis model: responses to disease induction and therapy with the estrogen receptor-beta selective agonist ERB-041. Endocrinology 147: 714-723.
44. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, et al. (2005) Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146: 3999-4008.
45. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, et al. (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A 95: 15677-15682.
46. Foryst-Ludwig A, Naumann M (2000) p21-activated kinase 1 activates the nuclear factor kappa B (NF-kappa B)-inducing kinase-Ikappa B kinases NFkappa B pathway and proinflammatory cytokines in Helicobacter pylori infection. J Biol Chem 275: 39779-39785.
47. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, et al. (2004) Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10: 1245-1250.